Log In
Print
BCIQ
Print
Print this Print this
 

Jublia, efinaconazole (IDP-108, KP-103)

  Manage Alerts
Collapse Summary General Information
Company Kaken Pharmaceutical Co. Ltd.
DescriptionTopical triazole antifungal
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationOnychomycosis
Indication DetailsTreat mild to moderate onychomycosis
Regulatory Designation

U.S. - Undisclosed Review (Treat mild to moderate onychomycosis);
Canada - Standard Review (Treat mild to moderate onychomycosis)

Partner

Valeant Pharmaceuticals International Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today